On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisher joined other contract development and manufacturing organizations in INOVIO’s global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800. With its consortium of third-party manufacturers, INOVIO planned to have 100 million doses of INO-4800 manufactured in 2021, subject to U.S. Food and Drug Administration (FDA) approval of INO-4800 for use as a COVID-19 vaccine.